Eli Lilly and Merck extend phase III Alimta-Keytruda study collaboration

Cercek: “The majority of patients in AZUR-1 in a global study were able to avoid all of standard of care”

On Oct. 19, FDA granted an accelerated approval to dostarlimab-gxly (Jemperli) for the treatment of patients with previously untreated stage 2 or stage 3 rectal cancer that is mismatch repair deficient or microsatellite instability–high, as determined by an FDA-authorized test.

November 04, 2026

NCI

NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprises
New NOFO aims to shrink applications by 40%

Late next month, NCI is expected to publish the new criteria it uses to bestow designations on America’s network of cancer centers.

NCAB ad hoc working group seeks to define its role as it approves eight reissue concepts
“We could do a lot more than be another committee to check the RFAs before they go to the next level.”

Members of the National Cancer Advisory Board’s ad hoc Working Group on Extramural Research Concepts and Programs at a recent meeting struggled to define the new group’s the role and raised concerns about some initial growing pains.

MSK’s Andrea Cercek: Oncology faces learning curve as dostarlimab challenges dMMR rectal cancer standard of care

Earlier this week, FDA granted an accelerated approval to dostarlimab-gxly (Jemperli), for adults with previously untreated stage 2 or stage 3 rectal cancer that is mismatch repair deficient or microsatellite instability-high, marking a celebratory moment for the field.

October 30, 2026

Vol.52 No.40

By Jacquelyn Cobb

Cancer History Project

Facing stage 4 cholangiocarcinoma, Keaton Herzer moved mountains to take off-label therapy, get a transplant
Two years later, he has no evidence of disease

Keaton Herzer had never even heard of cholangiocarcinoma when he was diagnosed in 2025.

October 30, 2026

Vol.52 No.40

By Deborah Doroshow and Sara Willa Ernst

Lifesaving vaccines: Using KRAS to harness the power of the immune system

Neeha Zaidi, MD, is turning the tables on pancreatic cancer. Mutations to a gene called KRAS—a cancer driver common to almost all pancreatic cancers—are now a target for prevention and treatment.

October 30, 2026

Vol.52 No.40

By Valerie Mehl

Eli Lilly and Merck extend phase III Alimta-Keytruda study collaboration

YOU MAY BE INTERESTED IN

Cercek: “The majority of patients in AZUR-1 in a global study were able to avoid all of standard of care”

NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprises
New NOFO aims to shrink applications by 40%

NCAB ad hoc working group seeks to define its role as it approves eight reissue concepts
“We could do a lot more than be another committee to check the RFAs before they go to the next level.”

MSK’s Andrea Cercek: Oncology faces learning curve as dostarlimab challenges dMMR rectal cancer standard of care

Facing stage 4 cholangiocarcinoma, Keaton Herzer moved mountains to take off-label therapy, get a transplant
Two years later, he has no evidence of disease

Lifesaving vaccines: Using KRAS to harness the power of the immune system

Renew today!

Subscriber content

Never miss an issue!

Login

Eli Lilly and Merck extend phase III Alimta-Keytruda study collaboration

YOU MAY BE INTERESTED IN

Cercek: “The majority of patients in AZUR-1 in a global study were able to avoid all of standard of care”

NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprisesNew NOFO aims to shrink applications by 40%

NCAB ad hoc working group seeks to define its role as it approves eight reissue concepts“We could do a lot more than be another committee to check the RFAs before they go to the next level.”

MSK’s Andrea Cercek: Oncology faces learning curve as dostarlimab challenges dMMR rectal cancer standard of care

Facing stage 4 cholangiocarcinoma, Keaton Herzer moved mountains to take off-label therapy, get a transplantTwo years later, he has no evidence of disease

Lifesaving vaccines: Using KRAS to harness the power of the immune system

Never miss an issue!

Login

NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprises
New NOFO aims to shrink applications by 40%

NCAB ad hoc working group seeks to define its role as it approves eight reissue concepts
“We could do a lot more than be another committee to check the RFAs before they go to the next level.”

Facing stage 4 cholangiocarcinoma, Keaton Herzer moved mountains to take off-label therapy, get a transplant
Two years later, he has no evidence of disease